GenWorks Health partners with Medtronic to redefine the treatment of intrauterine abnormalities
According to a study in the Journal of Obstetrics and Gynecology Sciences.
Yet despite its debilitating symptoms, such as heavy bleeding and periods that last more than a week, many women do not seek treatment.
Likewise, one in 10 women is known to suffer from endometriosis, a painful condition in which tissue similar to that which lines the inside of the uterus grows outside of the uterus. Yet less than half of these women are diagnosed or treated, why this neglect? Clinical studies have shown that a significant number of women find conventional treatment procedures too painful, time-consuming and frustrating.
Many gynecologists currently rely on an archaic, 175-year-old medical procedure known as “blind D&C” to diagnose and treat intrauterine abnormalities and diseases.
The procedure poses a serious health risk to patients due to its “poor diagnostic accuracy” and “incomplete resection of pathology”.
The procedure also fails to detect the very existence of tissues such as polyps and fibroids in the body due to the lack of ‘direct’ visual access. In 87% of cases, it was found that all or part of the lesion remained, according to data published on the Medtronic website. Medtronic is a world leader in medical technology. This was also true with retained products (RPOC) from conception or placental remnants, at the end of pregnancy, as blind D&C was known to remove only 40% of remnants, leading to bleeding and d other complications. COPD occurs in miscarriage and planned abortion. About 45% of pregnancies are unintended and therefore it is important to offer safe and complete disposal of remains.
But what if there was a much safer, minimally invasive way to diagnose and treat fibroids, polyps and other intrauterine abnormalities? Enter MHTR Western doctors have now moved on to innovations such as hysteroscopic mechanical tissue removal (MHTR) systems, in which the removal of pathologies, including fibroids or polyps, is treated on an outpatient basis without the need for medical procedures. general anesthesia nor the use of any thermal energy, a risky process that was previously used. MHTR also allows surgeons to see and treat in the same setting using a single insertion in addition to removing up to 98% of diseased tissue.
“The biggest benefit of using TruClear MHTR is that in over 80% of cases the procedure can be performed without anesthesia and also in an office with minimal pain for patients,” said Dr Milind. Telang, Consultant, Laparoscopic Gynecologist, Galaxy Care Hospital, Pune, who has treated over 200 cases using MHTR technology. “Because the technology allows to see and treat, unlike blind D&C, where you don’t know where the pathologies are, the procedure is more transparent. There is also no risk of injury or damage to the body. endometrium due to dispersion of electrical current, as the MHTR is based on mechanical energy Call for Action Docs With the technology now available, representatives from three major global gynecological societies – the global hysteroscopy community , the American Association for Gynecologic Laparoscopy and the European Society for Gynecologic Endoscopy – have called for an end to ‘blind gynecologic diagnostic and therapeutic interventions’ to protect women’s health, at a meeting held in Spain last month.
There are also many peer-reviewed studies, published in reputable journals, which have shown that MHTR systems are much better for the patient as they reduce complication rates, procedure time and result in fewer post-operative complications. procedural. As the Journal of Obstetrics & Gynecology Science observes, “New endoscopic devices will likely open up newer, safer, and more effective ways to treat and remove the most common benign tumors in women.” Announcing the partnership, Mr. Ganesh Prasad, Founder, MD and CEO of GenWorks Health, said, “Neonatal and women’s care is at the heart of GenWorks. While the last 2 decades have focused on the adoption of technology to save lives, the adoption of technology for the well-being of women is almost non-existent. GenWorks has made a pioneering effort to develop best-in-class technology for women’s well-being. We serve the maximum number of women’s health specialists in our country and are therefore able to implement solutions ranging from early detection to safe treatment. ” Mr. Prasad added, ”GenWorks’ strategy for women’s health is to have an impact on well-being and safe treatment. We believe that the value of women and their well-being is of paramount importance in everything we do. The addition of TruClear is a huge opportunity for safe treatment with almost no archaic practices that affect the well-being of our women.” Mr. Prasad added “Our women’s healthcare portfolio has been comprehensive since the early detection, early diagnosis, targeted treatment and development care. Our connected care platform provides access to specialists across the country and is impacting affordable access. We can proudly say that when it comes to women’s health, there is only GenWorks.” About GenWorks GenWorks is India’s leading healthcare startup dedicated to improving access to health care in India. GenWorks was originally a company invested by Wipro GE with the goal of creating a platform to solve the three fundamental challenges of healthcare – access, affordability and adoption. GenWorks was designed to bridge the gap of inadequacy in the healthcare industry by leveraging its close association with GE Healthcare, whose vision is “Working for a Healthier India”. GenWorks aims to provide quality care across the country. GenWorks is dedicated to raising awareness by leveraging available technology and providing affordable solutions across all geographies through its cutting-edge digital solutions, with a focus on improving specialist access for the latest kilometer.
(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)